IL150981A0 - Kahalalide derivatives and pharmaceutical compositions containing the same - Google Patents

Kahalalide derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL150981A0
IL150981A0 IL15098101A IL15098101A IL150981A0 IL 150981 A0 IL150981 A0 IL 150981A0 IL 15098101 A IL15098101 A IL 15098101A IL 15098101 A IL15098101 A IL 15098101A IL 150981 A0 IL150981 A0 IL 150981A0
Authority
IL
Israel
Prior art keywords
kahalalide
derivatives
same
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL15098101A
Other languages
English (en)
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of IL150981A0 publication Critical patent/IL150981A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Detergent Compositions (AREA)
IL15098101A 2000-02-09 2001-02-09 Kahalalide derivatives and pharmaceutical compositions containing the same IL150981A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002952.0A GB0002952D0 (en) 2000-02-09 2000-02-09 Process for producing kahalalide F compounds
PCT/GB2001/000576 WO2001058934A2 (en) 2000-02-09 2001-02-09 Kahalalide f and related compounds

Publications (1)

Publication Number Publication Date
IL150981A0 true IL150981A0 (en) 2003-02-12

Family

ID=9885232

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15098101A IL150981A0 (en) 2000-02-09 2001-02-09 Kahalalide derivatives and pharmaceutical compositions containing the same
IL150981A IL150981A (en) 2000-02-09 2002-07-30 Khalalid's History and Pharmaceuticals containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150981A IL150981A (en) 2000-02-09 2002-07-30 Khalalid's History and Pharmaceuticals containing them

Country Status (27)

Country Link
US (2) US7482429B2 (enExample)
EP (3) EP2258715A1 (enExample)
JP (1) JP5188665B2 (enExample)
KR (1) KR100871489B1 (enExample)
CN (2) CN1422278A (enExample)
AT (1) ATE371667T1 (enExample)
AU (1) AU783542B2 (enExample)
BG (1) BG65926B1 (enExample)
BR (1) BR0108213A (enExample)
CA (1) CA2399187C (enExample)
CY (1) CY1106992T1 (enExample)
CZ (1) CZ304258B6 (enExample)
DE (1) DE60130192T2 (enExample)
DK (1) DK1254162T3 (enExample)
ES (1) ES2292558T3 (enExample)
GB (1) GB0002952D0 (enExample)
HU (1) HUP0301817A3 (enExample)
IL (2) IL150981A0 (enExample)
MX (1) MXPA02007760A (enExample)
NO (1) NO331847B1 (enExample)
NZ (1) NZ520488A (enExample)
PL (1) PL207121B1 (enExample)
PT (1) PT1254162E (enExample)
RU (1) RU2280039C2 (enExample)
SK (1) SK11242002A3 (enExample)
UA (1) UA76949C2 (enExample)
WO (1) WO2001058934A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
US7473681B2 (en) 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
US20050054555A1 (en) * 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) * 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
CN100396696C (zh) * 2004-04-23 2008-06-25 中国科学院海洋研究所 一种海洋绿藻在提取抗肿瘤活性环肽组分中的应用
CN101861159A (zh) * 2007-10-19 2010-10-13 马尔药品公司 改进的抗肿瘤治疗
EP2252315A1 (en) * 2008-01-30 2010-11-24 Pharma Mar, S.A. Improved antitumoral treatments
AU2009221120A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved antitumoral treatments
CN103641891B (zh) * 2013-05-23 2017-03-22 深圳翰宇药业股份有限公司 一种制备Kahalalide F的方法
CN108283000B (zh) 2015-09-23 2021-04-13 凯瑞康宁生物工程(武汉)有限公司 γ-羟基丁酸的前药及其组合物和用途
KR102510784B1 (ko) 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程(武汉)有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
WO2021127461A1 (en) 2019-12-20 2021-06-24 Xw Laboratories Limited Methods of synthesizing 4-valyloxybutyric acid
KR102982616B1 (ko) 2020-06-18 2026-06-26 엑스더블유파마 리미티드 수용성 원료의약품의 약학적 과립화제
AU2021292406B2 (en) 2020-06-18 2024-03-14 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705B2 (en) 2020-10-05 2024-09-26 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
DK4308086T3 (da) 2021-03-19 2025-11-17 Xwpharma Ltd Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat
JP2025513295A (ja) * 2022-04-21 2025-04-24 ゼブラ セラピューティクス, インコーポレイテッド ガンマ-ヒドロキシブチラート送達化合物ならびにその作製および使用のためのプロセス

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39496A (en) * 1863-08-11 Improvement in ratchet-drills
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JPS6178719A (ja) 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
GR870129B (en) * 1987-01-27 1987-02-04 Giatzidis Ippokratis Stable bicarbonate - glycylglycine dialysate for hemodialysis and peritoneal dialysis
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU658396B2 (en) * 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
EP0567626B1 (en) * 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6274551B1 (en) * 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5932189A (en) * 1994-07-29 1999-08-03 Diatech, Inc. Cyclic peptide somatostatin analogs
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP3927248B2 (ja) 1995-07-11 2007-06-06 第一製薬株式会社 Hgf凍結乾燥製剤
US6391874B1 (en) * 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050406A1 (en) * 1997-05-09 1998-11-12 The General Hospital Corporation Cell proliferation related genes
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
CN1160338C (zh) * 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0002952D0 (en) * 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
JP2004514407A (ja) * 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US7473681B2 (en) 2000-10-31 2009-01-06 Pharma Mar, S.A. Kahalalide F
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
US7507708B2 (en) * 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Also Published As

Publication number Publication date
BG107020A (bg) 2003-05-30
JP2003522198A (ja) 2003-07-22
SK11242002A3 (sk) 2003-06-03
WO2001058934A3 (en) 2002-03-21
BG65926B1 (bg) 2010-05-31
EP1254162A2 (en) 2002-11-06
CN101597326A (zh) 2009-12-09
CY1106992T1 (el) 2012-09-26
DK1254162T3 (da) 2008-01-02
AU783542B2 (en) 2005-11-10
ES2292558T3 (es) 2008-03-16
GB0002952D0 (en) 2000-03-29
KR100871489B1 (ko) 2008-12-05
IL150981A (en) 2013-05-30
CZ304258B6 (cs) 2014-02-05
US20040214755A1 (en) 2004-10-28
RU2280039C2 (ru) 2006-07-20
WO2001058934A2 (en) 2001-08-16
RU2002123877A (ru) 2004-01-10
NO20023749L (no) 2002-10-07
PL207121B1 (pl) 2010-11-30
UA76949C2 (en) 2006-10-16
AU3208601A (en) 2001-08-20
HK1047290A1 (en) 2003-02-14
DE60130192D1 (de) 2007-10-11
EP2258715A1 (en) 2010-12-08
CA2399187A1 (en) 2001-08-16
HUP0301817A2 (hu) 2003-09-29
US7482429B2 (en) 2009-01-27
NO20023749D0 (no) 2002-08-08
MXPA02007760A (es) 2002-10-23
NO331847B1 (no) 2012-04-23
PL356800A1 (en) 2004-07-12
CA2399187C (en) 2011-04-19
BR0108213A (pt) 2003-03-05
CN1422278A (zh) 2003-06-04
EP1829889A2 (en) 2007-09-05
US20080318849A1 (en) 2008-12-25
DE60130192T2 (de) 2008-05-21
KR20020092951A (ko) 2002-12-12
CZ20022740A3 (cs) 2003-01-15
EP1829889A3 (en) 2007-09-26
NZ520488A (en) 2005-03-24
PT1254162E (pt) 2007-12-03
CN101597326B (zh) 2014-07-09
JP5188665B2 (ja) 2013-04-24
EP1254162B1 (en) 2007-08-29
ATE371667T1 (de) 2007-09-15
HUP0301817A3 (en) 2011-10-28

Similar Documents

Publication Publication Date Title
PL356800A1 (en) Kahalalide compounds
IL115790A0 (en) Pharmaceutical compositions containing boronic ester and acid compounds and methods for the preparation thereof
DE69804743D1 (de) Pyrazolo[4,3-d]pyrimidin-Derivate und diese enthaltende pharmazeutische Zubereitungen
IL147308A0 (en) Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
TW225532B (enExample)
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
HUT47376A (en) Insecticide compositions containing /p-phenoxy-phenoxy/-methyl-heteroaromatic compounds as active components and process for producing the active components
HUP0204157A3 (en) 1,3-dihydro-2h-indol-2-one derivatives, process for preparation of the compounds and pharmaceutical compositions containing the same
HUT65437A (en) Process for producing 4-benzoylisoxazole derivatives, herbicidal compositions containing the compunds as active ingredients and process for using thereof
IT1228288B (it) Composti ad attivita' antiserotoninica
BG102350A (en) New derivatives of 5-0-desozaminyl-6-0-methylerythronolide a, method for their preparation and usage for the preparation of biologically active products
FI945626A0 (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
AU696532B2 (en) Amidinophenylalanine derivatives, a process for their preparation, their use and compositions containing these as anticoagulants
IL113828A (en) Suspension concentrate compositions of arylpyrrole for use as insecticides and acaricides
AU2001260077A1 (en) Microfiltration using activated carbon
FI961378A0 (fi) Menetelmä N-metyyli-3-(1-metyyli-4-piperidinyyli)-14-indoli-5-etaanisulfonamidin valmistamiseksi
AU639913B2 (en) Compositions containing 2-thiocyanomethythiobenzothiazole for use as industrial microbicides
IL108997A0 (en) Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
BG105794A (en) (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for the production thereof and pharmaceutical compositions contaning the same
IT9022010A0 (it) Procedimento per la utilizzazione dirifiuti organici per la produzionedi biogas e di prodotti per l'agricoltura.
TW218011B (enExample)
ATE244239T1 (de) Polymorphe eines kristallinen azabicyclo(2,2,2) octan-3-amin citrat und diesen enthaltenden arzneimitteln
ZA909484B (en) Pyridylcarbamate compounds,process for preparing the same,and biological composition containing the same for controlling harmful organisms
IL141049A0 (en) Methoximinophenylacetic acid amides
EP0316639A3 (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient